Nicoletta Bernardini
Overview
Explore the profile of Nicoletta Bernardini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tolino E, Ambrosio L, Bernardini N, Proietti I, Skroza N, Potenza C
Dermatol Ther (Heidelb)
. 2025 Jan;
15(2):337-350.
PMID: 39862316
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4-7% of adults. This study evaluated the...
2.
Bernardini N, Dattola A, Rossi R, Pagnanelli G, Amerio P, Atzori L, et al.
J Pers Med
. 2024 Dec;
14(12).
PMID: 39728081
the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. this...
3.
Dattola A, Bernardini N, Svara F, Balato A, Caldarola G, DAmico D, et al.
J Dermatolog Treat
. 2024 Oct;
35(1):2420825.
PMID: 39462515
Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23,...
4.
Campione E, Artosi F, Shumak R, Giunta A, Argenziano G, Assorgi C, et al.
Pharmaceuticals (Basel)
. 2024 Oct;
17(10).
PMID: 39459016
(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic...
5.
Licata G, Tancredi V, Giuffrida G, Bernardini N, Zichichi L, Campione E
J Clin Aesthet Dermatol
. 2024 Oct;
17(10):18.
PMID: 39445327
No abstract available.
6.
Bernardini N, Skroza N, Atzori L, Mugheddu C, Megna M, Cacciapuoti S, et al.
Drugs Context
. 2024 Sep;
13.
PMID: 39263599
Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more...
7.
Proietti I, Svara F, Battilotti C, Dybala A, Ersilia T, Bernardini N, et al.
J Cosmet Dermatol
. 2024 Aug;
23(12):4380-4382.
PMID: 39165002
No abstract available.
8.
Dattola A, Bernardini N, Caldarola G, Coppola R, De Simone C, Giordano D, et al.
Dermatol Pract Concept
. 2024 Aug;
14(3).
PMID: 39122514
Introduction: This was an observational, retrospective, multicenter study, enrolling elderly patients (>65 years old) treated with ixekizumab with a diagnosis of psoriasis (PsO) and/or psoriatic arthritis (PsA) during the period...
9.
Galluzzo M, Trovato E, Talamonti M, Caldarola G, Di Nardo L, Lazzeri L, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999429
: Psoriatic disease, a chronic immune-mediated systemic inflammatory condition, significantly impairs patients' quality of life. The advent of highly targeted biological therapies has transformed treatment strategies, emphasizing the importance of...
10.
Dattola A, Bernardini N, Anedda J, Atzori L, Bonifati C, Bruni P, et al.
Ital J Dermatol Venerol
. 2024 Jun;
159(4):467-469.
PMID: 38829271
No abstract available.